About GLP-1 Treatments
How do GLP-1 treatments work?
Your gut releases GLP-1 after a meal. GLP-1 receptor agonists copy that signal through three pathways: they trigger insulin release from the pancreas when blood sugar rises, suppress glucagon (which cuts the liver’s glucose output), and slow gastric emptying so you feel full longer.
There are cardiovascular benefits too. In the SELECT trial, the FDA-approved branded version of semaglutide lowered the risk of major adverse cardiovascular events (MACE) by about 20% among adults with established cardiovascular disease and overweight or obesity but without diabetes, according to Lincoff et al. in the New England Journal of Medicine (2023).
One class distinction matters. Tirzepatide is a GLP-1/GIP dual agonist. It mimics both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), a second gut hormone. That’s a different mechanism from pure GLP-1 agonists, and it shows up in trial data.
Types of GLP-1 treatments
Several GLP-1 agents are available. They differ by ingredient, approved use, dosing frequency, and delivery form.
| Ingredient | Primary indication(s) | Dosing frequency | Delivery form | Notes |
| Semaglutide (injectable) | Type 2 diabetes; weight management; MASH (noncirrhotic, moderate-to-advanced fibrosis); cardiovascular risk reduction | Once weekly | Subcutaneous injection | Also available as oral tablet; strong weight-loss and cardiovascular trial data |
| Semaglutide (oral) | Type 2 diabetes; weight management; cardiovascular risk reduction | Once daily | Tablet | Take on empty stomach with no more than 4 oz water; wait 30 minutes before eating |
| Tirzepatide | Type 2 diabetes; weight management; obstructive sleep apnea | Once weekly | Subcutaneous injection | GLP-1/GIP dual agonist; among the highest weight-loss trial data to date (SURMOUNT-1) |
| Dulaglutide | Type 2 diabetes | Once weekly | Subcutaneous injection | Approved ages 10+; cardiovascular outcomes data (REWIND trial) |
| Liraglutide (diabetes dose) | Type 2 diabetes | Once daily | Subcutaneous injection | Generic available; approved ages 10+ |
| Liraglutide (weight-loss dose) | Weight management | Once daily | Subcutaneous injection | Generic available; approved ages 12+ |
| Exenatide | Type 2 diabetes | Twice daily | Subcutaneous injection | First FDA-approved GLP-1 (2005); generic available; no proven MACE benefit |
| Orforglipron | Weight management | Once daily | Oral tablet | Small-molecule (non-peptide); no food or water timing restrictions; newest agent in development |
Each ingredient has its own child page with dosing details, titration schedules, and cost information. A prescriber figures out which agent fits your goals and health profile.
Your Testing-to-Treatment Journey
Step 1: Lab tests to consider first
Baseline labs give a prescriber the full picture before starting any GLP-1 medication. These are the tests most likely to shape that conversation.
| Test | Why it’s reviewed | What different results suggest |
| Hemoglobin A1c | Reflects average blood sugar over roughly three months | A1c of 5.7–6.4% (prediabetes range) or ≥6.5% (diabetes range) means GLP-1 therapy can address both blood sugar and weight at the same time |
| Fasting Insulin Test | Catches insulin resistance that A1c can miss | High fasting insulin alongside other health markers points toward GLP-1 fit; a HOMA-IR score gives a clearer picture of insulin resistance severity |
| Lipid Panel | Cardiovascular risk context | High triglycerides and low HDL fit the metabolic pattern GLP-1 agents work on; cardiovascular outcomes are documented in the SELECT and REWIND trials |
| Comprehensive Metabolic Panel | Kidney function, electrolytes, liver markers | Baseline kidney and liver values matter before starting; GLP-1 agents affect gastric emptying and can cause dehydration with GI side effects |
Metabolic syndrome: know where you stand
Many GLP-1 candidates meet criteria for metabolic syndrome. The National Heart, Lung, and Blood Institute (NHLBI) defines it as having three or more of the following:
- Waist circumference over 40 inches (men) or 35 inches (women)
- Fasting blood glucose ≥100 mg/dL
- Triglycerides ≥150 mg/dL
- HDL cholesterol below 40 mg/dL (men) or 50 mg/dL (women)
- Blood pressure ≥130/85 mmHg
Knowing which criteria you meet helps a prescriber decide which markers to track on therapy.
If your A1c is in the prediabetes or diabetes range, your fasting insulin is high, and your lipid panel shows high triglycerides with low HDL, that pattern may strengthen the case for GLP-1 therapy. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that these medications are intended to complement, not replace, lifestyle changes. Talk with a licensed provider about what your full picture means.
Step 2: What happens during a prescriber consult
A prescriber reviews your health history, current medications, baseline labs, and treatment goals. They screen for key contraindications: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), history of pancreatitis, gastroparesis, and pregnancy. The Mayo Clinic’s semaglutide precautions guidance outlines these contraindications in detail for patients.
Weight-loss indications generally require a BMI of ≥30, or ≥27 with at least one weight-related condition. Some agents are approved for adolescents ages 12 and older or children ages 10 and older for the diabetes indication. Consultations are available through telehealth or in-person clinics.
Step 3: Starting therapy
All GLP-1 agents start low and go up gradually over weeks to months. That slow titration is intentional. It gives your body time to adjust and reduces GI side effects during the dose-up period.
The FDA-approved branded version of semaglutide, for example, starts at 0.25 mg weekly and escalates over 16 weeks. Tirzepatide starts at 2.5 mg weekly and steps up every four weeks. Your prescriber and pharmacy set the specific protocol for the agent you’re on. See the individual ingredient pages for dosing details.
Step 4: Labs to recheck on therapy
Monitoring labs tell you and your prescriber whether the medication is working and whether adjustments are needed.
| Recheck | Frequency | What it shows |
| Hemoglobin A1c | Every three months | Glycemic response to therapy |
| Comprehensive metabolic panel (CMP) | Every three to six months | Kidney function, electrolytes, liver markers |
| Lipid panel | Every six months | Cardiovascular response; triglycerides and HDL usually improve |
| Weight | Weekly to monthly | Progress toward goal; informs dose adjustment timing |
| Fasting glucose | As clinically indicated | Hypoglycemia risk when combined with insulin or sulfonylureas |
From the Testing.com Medical Review Board
“The first six to 12 weeks on a GLP-1 agent tell you a lot about protocol fit. If someone’s weight isn’t moving at all by week eight and GI side effects have settled, that’s a signal to revisit the dose or the agent, not to wait until the 16-week mark. Early A1c and fasting glucose trends are equally useful: a meaningful drop in fasting glucose within the first month often predicts a strong glycemic response at the three-month A1c check. Monitoring labs aren’t just a safety net. They’re the feedback loop that makes titration decisions defensible.”
Testing.com Editorial Review Board
Safety and Side Effects
Common side effects
Nausea, vomiting, diarrhea, constipation, reduced appetite, and injection-site reactions (for injectable forms) are the most reported side effects across GLP-1 trials. Most peak during dose escalation. They usually improve as your body adjusts. Side effect profiles are similar across the class but vary by agent and person.
How to manage them
Prescribers use a few specific tactics. Holding the dose longer before escalating helps when nausea is severe. Eating smaller, more frequent meals helps too. Avoiding high-fat foods around injection day reduces GI symptoms for injectable forms. Stay well hydrated to address constipation. Specific adjustments depend on the prescriber’s assessment.
Serious risks and contraindications
GLP-1 receptor agonists carry a class-wide boxed warning for thyroid C-cell tumors, based on animal studies. Don’t start a GLP-1 agent if you have a personal or family history of MTC or MEN2, a history of pancreatitis, severe GI conditions such as gastroparesis, or if you’re pregnant or breastfeeding.
Gallbladder issues like gallstones can come up, partly because rapid weight loss itself raises that risk and these drugs may affect gallbladder motility. Let your prescriber know about sudden or severe abdominal pain.
If you have diabetes with existing diabetic retinopathy, mention it before starting. Quick drops in blood sugar can briefly worsen it, so an eye check before or soon after starting is a reasonable precaution.
Serious digestive problems are uncommon. Still, the FDA notes that GLP-1 drugs can occasionally cause ileus or intestinal obstruction, and the ADA suggests avoiding them if you have significant gastroparesis or a history of recurrent ileus or bowel obstruction. Because these drugs slow stomach emptying, prescribers often pause them before surgery or an endoscopy (about a week for once-weekly agents) as a precaution against aspiration. Reach out to your prescriber for severe or persistent abdominal pain, vomiting, or constipation.
Reports of suicidal thoughts or depression have come up with weight-management formulations, and the FDA has flagged them. A 2025 meta-analysis didn’t find a statistically significant increase, but it’s still worth telling your prescriber right away about new or worsening depression or any thoughts of self-harm.
Go over your full medical history with your prescriber before starting.
Drug and supplement interactions
Slowed gastric emptying affects how your body absorbs oral medications taken at the same time. Three categories need attention:
- Insulin, sulfonylureas, and meglitinides require closer monitoring for low blood sugar (hypoglycemia)
- Oral medications with narrow therapeutic windows may need timing changes
- GLP-1 agents shouldn’t be combined with other GLP-1 agonists
Some newer agents have specific interactions. Orforglipron should be avoided with strong CYP3A4 inhibitors that also inhibit OATP1B transporters (such as ritonavir), as well as with strong CYP3A4 inducers, per orforglipron’s product labeling. Share your full medication and supplement list with your prescriber.
Stopping the medication
GLP-1 effects don’t last after you stop. In the STEP-4 trial, people who switched from the FDA-approved branded version of semaglutide to placebo regained roughly two-thirds of their lost weight within one year, as reported by Rubino et al. in JAMA (2021).
Appetite increases and blood sugar changes are common after stopping, especially for people managing diabetes. Your prescriber can walk you through a taper plan or a direct stop depending on your situation. Build a stopping plan before you start, not after.
Cost and Access
Cost ranges as of May 2026. Pricing varies by pharmacy and shortage status; confirm with the dispensing pharmacy before committing to a multi-month plan.
Typical cost
Newer FDA-approved branded GLP-1 agents run roughly $900 to $1,350 per month out of pocket without insurance. Older agents with generics, including liraglutide (both the diabetes and weight-loss doses) and exenatide, cost significantly less. Insurance coverage varies widely. Plans are more likely to cover GLP-1 agents for a diabetes diagnosis than for weight loss alone, and many weight-loss indications require pre-authorization.
How to get it
All GLP-1 agents are prescription-only. You can reach a prescriber through telehealth platforms that connect you with licensed providers, or through in-person clinics including primary care, endocrinology, and obesity medicine practices. Insurance pre-authorization is often required for weight-loss indications, so it’s worth checking your plan before your appointment. These lab tests can be ordered through a healthcare provider, clinic, or hospital lab.
Frequently Asked Questions
Sources
National Heart, Lung, and Blood Institute. Metabolic Syndrome. NIH.
Cleveland Clinic. GLP-1 Agonists.